BioStock: Aptahem on the comparative study between Apta-1 and dexamethasone
For half a century Dexamethasone has been used to treat diseases such as rheumatoid arthritis and asthma. Four years ago, Malmö-based Aptahem was able to present preclinical data that indicate that Apta-1 in some important aspects is better than dexamethasone in hyper inflammatory conditions. A British study recently found that dexamethasone significantly reduces the risk of death from Covid-19. BioStock reached out to the company’s CSO Luiza Jedlina for a comment.
Read the full interview with Luiza Jedlina at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se